| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 3.77 | 0.04 (+1.07%) | 3.35 - 11.44 | 440.1 thousand (Below Avg) |
Market data as of 4:00PM 06/18/13. Quotes are delayed by at least 15 min.
| Open | 3.73 |
|---|---|
| Previous Close | 3.73 |
| Day's Range | 3.68 - 3.77 |
| Market Cap | 328.5M |
| Avg Volume (10 Day) | 958.3K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -1.29 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Pass |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Rigel Will Resume Responsibility for Fostamatinib Program
PR Newswire - Tuesday 06/04/2013 2:00 AM ET
Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye
PR Newswire - Wednesday 05/22/2013 7:30 AM ET
| RIGL | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -72.73% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.00 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | -- | |
| Price/Sales | 216.69 |
| Company | Last | Change |
|---|---|---|
| AcelRx Pharmaceuticals Inc | 9.60 | -3.23% |
| TherapeuticsMD Inc | 2.89 | 0.00% |
| Star Scientific Inc | 1.45 | +3.57% |
| Ampio Pharmaceuticals Inc | -- | -- |
| Raptor Pharmaceutical Corp | 7.83 | +3.43% |
Data is delayed by at least 15 min.